Polaryx Therapeutics(PLYX)
PARAMUS, NJBiotechnology
Focus: Polaryx Therapeutics is a publicly traded biotech focused on small molecule and gene therapy treatments for lysosomal storage disorders and repurposed drugs in the rare disease space. The company operates at a modest scale with minimal cash reserves and a highly focused pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Polaryx Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Polaryx Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 3
Clinical Trials (1)
NCT04637282Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
Phase 3Help build intelligence for Polaryx Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.